keyword
MENU ▼
Read by QxMD icon Read
search

Parkinson's and PET scan

keyword
https://www.readbyqxmd.com/read/27914043/a-revisit-to-quantitative-pet-with-18-f-fdopa-of-high-specific-activity-using-a-high-resolution-condition-in-view-of-application-to-regenerative-therapy
#1
Go Akamatsu, Akihito Ohnishi, Kazuki Aita, Hiroyuki Nishida, Yasuhiko Ikari, Masahiro Sasaki, Nobuo Kohara, Michio Senda
OBJECTIVE: With the advent of regenerative/cell therapy for Parkinson's disease (PD), (18)F-FDOPA has drawn new attention as a biomarker of the therapeutic that cannot be evaluated with radiopharmaceuticals for dopamine transporter. Since most previous (18)F-FDOPA PET studies were carried out many years ago with a PET scanner of lower resolution and with (18)F-FDOPA of low specific activity synthesized from (18)F-F2, we used a newer PET/CT scanner with a high-resolution condition and (18)F-FDOPA synthesized from (18)F-F(-) to re-evaluate this technique on normal subjects and patients with PD, together with D2 receptor imaging with (11)C-raclopride (RAC)...
December 2, 2016: Annals of Nuclear Medicine
https://www.readbyqxmd.com/read/27893588/suite-pet-ct-neuroimaging-for-the-diagnosis-of-parkinson-s-disease-statistical-parametric-mapping-analysis
#2
Ruimin Wang, Baixuan Xu, Zhe Guo, Tong Chen, Jinming Zhang, Yingmao Chen, Haiyan Zhu
OBJECTIVES: The aim of this study was to investigate the topographical distribution of dopamine transporter (DAT), dopamine D2 receptor, and glucose metabolism in Parkinson's disease (PD) using PET/computed tomography (CT) scanning and statistical parametric mapping (SPM) analysis. PARTICIPANTS AND METHODS: Seventy-four patients (58 PD patients and 16 normal controls) underwent DAT, D2 receptor, and glucose brain PET/CT scans using C-methyl-N-2-β-carbomethoxy-3-β-(4-fluorophenyl) tropane (C-β-CFT), C-raclopride (C-RAC), and fluorine-18-fluorodeoxyglucose (F-FDG) radiotracers for the respective scans...
November 28, 2016: Nuclear Medicine Communications
https://www.readbyqxmd.com/read/27862279/pet-and-mri-detection-of-early-and-progressive-neurodegeneration-in-spinocerebellar-ataxia-type-36
#3
Pablo Aguiar, Julio Pardo, Manuel Arias, Beatriz Quintáns, Montse Fernández-Prieto, Rocío Martínez-Regueiro, José-Manuel Pumar, Jesús Silva-Rodríguez, Álvaro Ruibal, María-Jesús Sobrido, Julia Cortés
BACKGROUND: The spinocerebellar ataxias (SCAs) form a clinically, genetically, and pathological heterogeneous group of autosomal-dominant degenerative diseases. In particular, SCA36 is characterized by a late-onset, slowly progressive cerebellar syndrome typically associated with sensorineural hearing loss. This study was aimed at analyzing the neurodegenerative process underlying SCA36 through fluorodeoxyglucose positron emission tomography (FDG-PET) and MRI scans. METHODS: Twenty SCA36 patients underwent a study consisting of FDG-PET and MRI scans...
November 10, 2016: Movement Disorders: Official Journal of the Movement Disorder Society
https://www.readbyqxmd.com/read/27859651/sustained-striatal-dopamine-levels-following-intestinal-levodopa-infusions-in-parkinson-s-disease-patients
#4
Marios Politis, Anna Sauerbier, Clare Loane, Nicola Pavese, Anne Martin, Benjamin Corcoran, David J Brooks, K Ray-Chaudhuri, Paola Piccini
BACKGROUND: The objective of this study was to investigate in vivo the ability of levodopa/carbidopa intestinal gel infusions to produce sustained striatal dopamine levels and to improve clinical outcomes in Parkinson's disease patients. METHODS: Six advanced Parkinson's disease patients had serial [(11) C]raclopride PET to assess levodopa/carbidopa intestinal gel infusion-induced rises in striatal dopamine as reflected by a fall in dopamine-D2/3 receptor availability...
November 17, 2016: Movement Disorders: Official Journal of the Movement Disorder Society
https://www.readbyqxmd.com/read/27817842/-pregabalin-induced-parkinsonism-a-case-report
#5
Inès Masmoudi, Valérie Gras-Champel, Dominique Barbieux-Vaquez, Kamel Masmoudi
Pregabalin is not known to induce parkinsonism, one single case is published in the literature. In this work, we report the second case of parkinsonism-induced by this drug in a 58-year old woman initially dosed at 600mg daily for 3 years which was reduced to 300mg daily after the onset of myoclonic jerks and especially because of a weight gain. She is regularly monitored by a neurologist who notes the onset of a parkinsonian syndrome whose asymmetry clinical picture mimicking an idiopathic Parkinson's disease but positron emission tomography (PET scan) was normal and the brain magnetic resonance imaging MRI found a banal leukopathy...
October 15, 2016: Thérapie
https://www.readbyqxmd.com/read/27708130/distinct-brain-networks-underlie-cognitive-dysfunction-in-parkinson-and-alzheimer-diseases
#6
Paul J Mattis, Martin Niethammer, Wataru Sako, Chris C Tang, Amir Nazem, Marc L Gordon, Vicky Brandt, Vijay Dhawan, David Eidelberg
OBJECTIVE: To determine whether cognitive impairment in Parkinson disease (PD) and Alzheimer disease (AD) derives from the same network pathology. METHODS: We analyzed (18)F-fluorodeoxyglucose PET scans from 40 patients with AD and 40 age-matched healthy controls from the Alzheimer's Disease Neuroimaging Initiative and scanned an additional 10 patients with AD and 10 healthy controls at The Feinstein Institute for Medical Research to derive an AD-related metabolic pattern (ADRP) analogous to our previously established PD cognition-related pattern (PDCP) and PD motor-related pattern (PDRP)...
November 1, 2016: Neurology
https://www.readbyqxmd.com/read/27571419/fatigue-in-parkinson-s-disease-the-contribution-of-cerebral-metabolic-changes
#7
Sang Soo Cho, Kelly Aminian, Crystal Li, Anthony E Lang, Sylvain Houle, Antonio P Strafella
Fatigue is a common and disabling non-motor symptom in Parkinson's disease associated with a feeling of overwhelming lack of energy. The aim of this study was to identify the neural substrates that may contribute to the development of fatigue in Parkinson's disease. Twenty-three Parkinson's disease patients meeting UK Brain Bank criteria for the diagnosis of idiopathic Parkinson's disease were recruited and completed the 2-[(18) F]fluoro-2-deoxy-D-glucose (FDG)-PET scan. The metabolic activities of Parkinson's disease patients with fatigue were compared to those without fatigue using statistical parametric mapping analysis...
August 29, 2016: Human Brain Mapping
https://www.readbyqxmd.com/read/27544483/dissociation-of-metabolic-and-hemodynamic-levodopa-responses-in-the-6-hydroxydopamine-rat-model
#8
Renata P Lerner, Zisis Bimpisidis, Stergiani Agorastos, Sandra Scherrer, Stephen L Dewey, M Angela Cenci, David Eidelberg
Dissociation of vasomotor and metabolic responses to levodopa has been observed in human subjects with Parkinson's disease (PD) studied with PET and in autoradiograms from 6-hydroxydopamine (6-OHDA) rat. In both species, acute levodopa administration was associated with increases in basal ganglia cerebral blood flow (CBF) with concurrent reductions in cerebral metabolic rate (CMR) for glucose in the same brain regions. In this study, we used a novel dual-tracer microPET technique to measure CBF and CMR levodopa responses in the same animal...
December 2016: Neurobiology of Disease
https://www.readbyqxmd.com/read/27539837/2-year-natural-decline-of-cardiac-sympathetic-innervation-in-idiopathic-parkinson-disease-studied-with-11c-hydroxyephedrine-hed-pet
#9
Ka Kit Wong, David M Raffel, Nicolaas I Bohnen, Gulchin Altinok, Sid Gilman, Kirk A Frey
OBJECTIVE: To detect regional patterns of cardiac sympathetic denervation in idiopathic Parkinson disease (IPD) using (11)C-hydroxyephedrine (HED) PET and determine the denervation rate over 2 years. BACKGROUND: In IPD, Lewy body accumulation in cardiac autonomic ganglia leads to extensive cardiac sympathetic neuronal loss, as demonstrated on (123)I-metaiodobenzylguanidine ((123)I-MIBG) imaging and in (11)C-HED and (18)F-fluorodopamine ((18)F-DA) PET. The natural history of onset and progression of cardiac sympathetic denervation has not been determined...
August 18, 2016: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/27529171/striatal-dopamine-depletion-patterns-and-early-non-motor-burden-in-parkinsons-disease
#10
Su Jin Chung, Jae Jung Lee, Jee Hyun Ham, Byoung Seok Ye, Phil Hyu Lee, Young H Sohn
BACKGROUND: The mechanism underlying non-motor symptoms in Parkinson's disease has not yet been elucidated. In this study, we hypothesized that Parkinson patients with more non-motor symptoms have a different pattern of striatal dopamine depletion, particularly in areas other than the sensorimotor striatum, compared to those with fewer non-motor symptoms. METHODS: We conducted a prospective survey of the degree of non-motor symptoms (using the Korean version of the Non-Motor Symptoms Scale; K-NMSS) in 151 patients with early-stage Parkinson's disease who had undergone a dopamine transporter PET scan as an initial diagnostic procedure...
2016: PloS One
https://www.readbyqxmd.com/read/27500181/amyloid-beta-positron-emission-tomography-imaging-of-alzheimer-s-pathology-in-parkinson-s-disease-dementia
#11
Rizwan S Akhtar, Sharon X Xie, Laura Brennan, Michael J Pontecorvo, Howard I Hurtig, John Q Trojanowski, Daniel Weintraub, Andrew D Siderowf
BACKGROUND: Neuronal loss and α-synuclein (α-syn) pathology are diagnostic of PD in the appropriate clinical context. However, some PD patients have co-morbid Alzheimer's disease (AD) pathology on autopsy, including amyloid-β (Aβ) plaques and neurofibrillary tangles. Florbetapir((18)F) is a PET ligand that detects Aβ pathology. We hypothesized that florbetapir((18)F) imaging could detect Aβ pathology in Parkinson disease dementia (PDD) patients prior to death. OBJECTIVE: To determine the utility of florbetapir((18)F) PET imaging in detecting Aβ pathology in patients with autopsy-confirmed PDD...
July 2016: Movement Disorders Clinical Practice
https://www.readbyqxmd.com/read/27489875/white-matter-hyperintensities-are-more-highly-associated-with-preclinical%C3%A2-alzheimer-s-disease-than-imaging-and-cognitive-markers-of%C3%A2-neurodegeneration
#12
Benjamin M Kandel, Brian B Avants, James C Gee, Corey T McMillan, Guray Erus, Jimit Doshi, Christos Davatzikos, David A Wolk
INTRODUCTION: Cognitive tests and nonamyloid imaging biomarkers do not consistently identify preclinical AD. The objective of this study was to evaluate whether white matter hyperintensity (WMH) volume, a cerebrovascular disease marker, is more associated with preclinical AD than conventional AD biomarkers and cognitive tests. METHODS: Elderly controls enrolled in the Alzheimer's Disease Neuroimaging Initiative (ADNI, n = 158) underwent florbetapir-PET scans, psychometric testing, neuroimaging with MRI and PET, and APOE genetic testing...
2016: Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
https://www.readbyqxmd.com/read/27334907/altered-striatal-circuits-underlie-characteristic-personality-traits-in-parkinson-s-disease
#13
Toru Ishii, Nobukatsu Sawamoto, Hayato Tabu, Hidekazu Kawashima, Tomohisa Okada, Kaori Togashi, Ryosuke Takahashi, Hidenao Fukuyama
Patients with Parkinson's disease (PD) have been suggested to share personality traits characterised by low novelty-seeking and high harm-avoidance. Although a link between novelty-seeking and dopamine is hypothesised, the link is not fully supported by 6-[(18)F]fluoro-L-dopa positron emission tomography (PET) studies. Meanwhile, tractography studies with magnetic resonance imaging (MRI) link personality to the connectivity of the striatum in healthy subjects. Here, we investigated neurochemical and anatomical correlates of characteristic personality traits in PD...
September 2016: Journal of Neurology
https://www.readbyqxmd.com/read/27299437/extrastriatal-spreading-of-microglial-activation-in-parkinson-s-disease-a-positron-emission-tomography-study
#14
Tatsuhiro Terada, Masamichi Yokokura, Etsuji Yoshikawa, Masami Futatsubashi, Satoshi Kono, Takashi Konishi, Hiroaki Miyajima, Takanori Hashizume, Yasuomi Ouchi
BACKGROUND: The neuroinflammatory glial response contributes to the degenerative process in Parkinson's disease (PD). However, the pattern of microglial progression remains unclear. METHODS: We evaluated microglial activation in early stage PD patients by quantifying changes in neuroinflammation using PET with [(11)C]DPA713, a selective PET tracer for microglial activation. Eleven PD patients (Hoehn and Yahr stages 1-2) without dementia underwent the [(11)C]DPA713 PET scan two times with 1 year apart...
October 2016: Annals of Nuclear Medicine
https://www.readbyqxmd.com/read/27207613/parkinson-s-disease-related-network-topographies-characterized-with-resting-state-functional-mri
#15
An Vo, Wataru Sako, Koji Fujita, Shichun Peng, Paul J Mattis, Frank M Skidmore, Yilong Ma, Aziz M Uluğ, David Eidelberg
Spatial covariance mapping can be used to identify and measure the activity of disease-related functional brain networks. While this approach has been widely used in the analysis of cerebral blood flow and metabolic PET scans, it is not clear whether it can be reliably applied to resting state functional MRI (rs-fMRI) data. In this study, we present a novel method based on independent component analysis (ICA) to characterize specific network topographies associated with Parkinson's disease (PD). Using rs-fMRI data from PD and healthy subjects, we used ICA with bootstrap resampling to identify a PD-related pattern that reliably discriminated the two groups...
May 21, 2016: Human Brain Mapping
https://www.readbyqxmd.com/read/27190023/in-vivo-imaging-of-neuromelanin-in-parkinson-s-disease-using-18f-av-1451-pet
#16
Allan K Hansen, Karoline Knudsen, Thea P Lillethorup, Anne M Landau, Peter Parbo, Tatyana Fedorova, Hélène Audrain, Dirk Bender, Karen Østergaard, David J Brooks, Per Borghammer
The tau tangle ligand (18)F-AV-1451 ((18)F-T807) binds to neuromelanin in the midbrain, and may therefore be a measure of the pigmented dopaminergic neuronal count in the substantia nigra. Parkinson's disease is characterized by progressive loss of dopaminergic neurons. Extrapolation of post-mortem data predicts that a ∼30% decline of nigral dopamine neurons is necessary to cause motor symptoms in Parkinson's disease. Putamen dopamine terminal loss at disease onset most likely exceeds that of the nigral cell bodies and has been estimated to be of the order of 50-70%...
July 2016: Brain: a Journal of Neurology
https://www.readbyqxmd.com/read/27150035/compartmental-modeling-of-11-c-menet-binding-to-the-norepinephrine-transporter-in-the-healthy-human-brain
#17
Vikram Adhikarla, Fanxing Zeng, John R Votaw, Mark M Goodman, Jonathon A Nye
INTRODUCTION: Dysregulation of the noradrenergic system has been implicated in a number of neurological conditions such as Parkinson's and Alzheimer's. [(11)C]MENET is a novel PET radiotracer with high affinity and selectivity for the norepinephrine transporter. The applicability of different kinetic models on [(11)C]MENET PET image quantification in healthy population is evaluated. METHODS: Six healthy volunteers (mean age: 54years) were recruited for the study, five of whom underwent arterial sampling for measurement of the input function...
May 2016: Nuclear Medicine and Biology
https://www.readbyqxmd.com/read/27082948/the-effect-of-endogenous-adenosine-on-neuronal-activity-in-rats-an-fdg-pet-study
#18
Fiona E Parkinson, Soumen Paul, Dali Zhang, Shadreck Mzengeza, Ji Hyun Ko
2-(18) F-fluorodeoxy-D-glucose (FDG) is a glucose analog that is taken up by cells and phosphorylated. The amount of FDG accumulated by cells is a measure of the rate of glycolysis, which reflects cellular activity. As the levels and actions of the neuromodulator adenosine are dynamically regulated by neuronal activity, this study was designed to test whether endogenous adenosine affects tissue accumulation of FDG as assessed by positron emission tomography (PET) or by postmortem analysis of tissue radioactivity...
July 2016: Journal of Neuroimaging: Official Journal of the American Society of Neuroimaging
https://www.readbyqxmd.com/read/27069770/the-sensitivity-and-specificity-of-f-dopa-pet-in-a-movement-disorder-clinic
#19
Nevein Ibrahim, Joanna Kusmirek, Aaron F Struck, John M Floberg, Scott B Perlman, Catherine Gallagher, Lance T Hall
Idiopathic Parkinson's disease (PD) is the second most common neurodegenerative disorder. Early PD may present a diagnostic challenge with broad differential diagnoses that are not associated with nigral degeneration or striatal dopamine deficiency. Therefore, the early clinical diagnosis alone may not be accurate and this reinforces the importance of functional imaging targeting the pathophysiology of the disease process. (18)F-DOPA L-6-[(18)F] fluoro-3,4-dihydroxyphenylalnine ((18)F-DOPA) is a positron emission tomography (PET) agent that measures the uptake of dopamine precursors for assessment of presynaptic dopaminergic integrity and has been shown to accurately reflect the monoaminergic disturbances in PD...
2016: American Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/27069768/-11-c-pib-pet-in-gerstmann-str%C3%A3-ussler-scheinker-disease
#20
Kacie D Deters, Shannon L Risacher, Karmen K Yoder, Adrian L Oblak, Frederick W Unverzagt, Jill R Murrell, Francine Epperson, Eileen F Tallman, Kimberly A Quaid, Martin R Farlow, Andrew J Saykin, Bernardino Ghetti
Gerstmann-Sträussler-Scheinker Disease (GSS) is a familial neurodegenerative disorder characterized clinically by ataxia, parkinsonism, and dementia, and neuropathologically by deposition of diffuse and amyloid plaques composed of prion protein (PrP). The purpose of this study was to evaluate if [(11)C]Pittsburgh Compound B (PiB) positron emission tomography (PET) is capable of detecting PrP-amyloid in PRNP gene carriers. Six individuals at risk for GSS and eight controls underwent [(11)C]PiB PET scans using standard methods...
2016: American Journal of Nuclear Medicine and Molecular Imaging
keyword
keyword
60911
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"